AQST is trading about 5.3% down at $4.48 in pre-market, giving back part of its 14.53% surge from the May 14 close at $4.73.
- The stock previously jumped following a first-quarter report showing 66% revenue growth, stronger license and royalty income, and reaffirmed full-year guidance.
- Management highlighted a de-risked regulatory and refinancing roadmap for Anaphylm; today's move appears to be profit-taking and normalization following that spike.